Please login to the form below

Not currently logged in
Email:
Password:

Relay Therapeutics strengthens team

Don Bergstorm, Brian Adams and Tom Catinazzo join the biotech

Relay Therapeutics has appointed a new executive vice president, head of research and development in the form of Don Bergstorm.

Bergstorm joins the biotech from Mersana Therapeutics, where he led the advancement of two oncology products.

Prior to this, he was at Sanofi Oncology, where he held a global translational and experimental medicine position.

Relay Therapeutics has also appointed Brian Adams, who joins as its general counsel, bringing more than 15 years of legal and business management experience within the life science sector.

He has held roles for Keryx Biopharmaceutical, Algeta ASA and AVEO Oncology.

Last but not least, Tom Catinazzo has also joined Relay Therapeutics as its new vice president of finance.

Catinazzo brings over 12 years’ experience in the biotech field having worked at Aileron Therapeutics and Genzyme Corporation supporting both the renal and personalised genetic health division.

Sanjiv Patel, chief executive officer of Relay Therapeutics, said: “We welcome Don, Brian and Tom to the senior team at Relay Therapeutics.

“These seasoned leaders will help us to deliver transformational therapies using our novel integrated experimental and computational platform.

“We will continue to grow and add team members as our portfolio matures towards clinical development, and anticipate a move to our new headquarters in late 2018.”

23rd April 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics